VPC
DYN icon

Vestal Point Capital’s Dyne Therapeutics DYN Stock Holding History

Vestal Point Capital’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$72.5M Buy
4,000,000
+3,880,000
+3,233% +$66.9M 2.03% 14
2025
Q4 		$2.35M Sell
120,000
-2,655,000
-96% -$50.3M 0.08% 69
2025
Q3 		$35.1M Buy
2,775,000
+2,047,500
+281% +$23.4M 1.59% 23
2025
Q2 		$6.93M Sell
727,500
-1,072,500
-60% -$11.8M 0.36% 50
2025
Q1 		$18.8M Buy
+1,800,000
New +$25.7M 1.34% 24
2024
Q3 		– Sell
-225,000
Closed -$7.94M – 75
2024
Q2 		$7.94M Buy
+225,000
New +$6.54M 0.59% 39

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Vestal Point Capital's DYN Position: Q1 2026 in Review

Vestal Point Capital increased its Dyne Therapeutics (DYN) stake by 3,233% in Q1 2026, buying an estimated $66.9M and bringing the position to 4,000,000 shares worth $72.5M. The position accounts for 2.03% of the portfolio, ranked #14.

Vestal Point Capital first reported a position in DYN in Q2 2024 and has held it in 6 quarters since. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Vestal Point Capital held 4,000,000 shares of Dyne Therapeutics worth $72.5M as of Q1 2026.
  • Vestal Point Capital bought 3,880,000 Dyne Therapeutics shares in Q1 2026, an estimated $66.9M.
  • Dyne Therapeutics made up 2.03% of Vestal Point Capital's portfolio in Q1 2026, its #14 holding.
  • Vestal Point Capital first reported a position in Dyne Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.